$10.56
8.09% yesterday
Nasdaq, Sep 23, 10:14 pm CET
ISIN
US45257U1088
Symbol
IMNM

Immunome Inc Stock price

$10.56
+0.64 6.45% 1M
+2.41 29.57% 6M
-0.06 0.57% YTD
-3.44 24.57% 1Y
+5.81 122.32% 3Y
-2.89 21.49% 5Y
-2.89 21.49% 10Y
-2.89 21.49% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
+0.79 8.09%
ISIN
US45257U1088
Symbol
IMNM
Industry

Key metrics

Basic
Market capitalization
$850.4m
Enterprise Value
$582.4m
Net debt
positive
Cash
$268.0m
Shares outstanding
87.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
67.5 | 120.4
EV/Sales
46.3 | 82.4
EV/FCF
negative
P/B
3.2
Financial Health
Equity Ratio
75.4%
Return on Equity
-161.7%
ROCE
-69.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$12.6m | $7.1m
EBITDA
$-187.7m | $-198.9m
EBIT
$-190.5m | $-201.3m
Net Income
$-212.4m | $-196.7m
Free Cash Flow
$-196.8m
Growth (TTM | estimate)
Revenue
16.7% | -21.8%
EBITDA
-162.3% | -31.4%
EBIT
-162.7% | -31.2%
Net Income
19.1% | 32.9%
Free Cash Flow
-83.5%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,490.9% | -2,814.9%
EBIT
-1,513.5%
Net
-1,687.1% | -2,783.8%
Free Cash Flow
-1,563.1%
More
EPS
$-2.4
FCF per Share
$-2.3
Short interest
16.3%
Employees
155
Rev per Employee
$60.0k
Show more

Is Immunome Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Immunome Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Immunome Inc forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Immunome Inc forecast:

Buy
94%
Hold
6%

Financial data from Immunome Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
13 13
17% 17%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 41 41
59% 59%
323%
- Research and Development Expense 162 162
181% 181%
1,290%
-188 -188
162% 162%
-1,491%
- Depreciation and Amortization 2.84 2.84
196% 196%
23%
EBIT (Operating Income) EBIT -191 -191
163% 163%
-1,513%
Net Profit -212 -212
19% 19%
-1,687%

In millions USD.

Don't miss a Thing! We will send you all news about Immunome Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunome Inc Stock News

Positive
Proactive Investors
about 9 hours ago
Immunome, Inc (NASDAQ: IMNM) has a “rich pipeline of potential best and/or first-in-class targeted oncology therapeutics,” Goldman Sachs analysts wrote in a note to clients on Monday.   They initiated coverage on Immunome stock with a ‘Buy' rating and 12-month target price of $26 per share.
Neutral
Business Wire
6 days ago
ALAMEDA, Calif.--(BUSINESS WIRE)-- #antibodies--Infinimmune Announces Research Collaboration with Immunome.
Neutral
Business Wire
19 days ago
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Sept. 2, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchas...
More Immunome Inc News

Company Profile

Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.

Head office United States
CEO Clay Siegall
Employees 155
Founded 2006
Website immunome.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today